Pharma

Your Article Summary

See Latest Articles

Par pharmaceutical reports eps of $0.71 for second quarter 2009
Par Pharmaceutical, 08/05/09

Par Pharmaceutical Companies, Inc. reported results for the second quarter ended June 2009. For the second quarter ended June 2009, Par reported total revenues of $404.0 million and net income of $23.8 million, or $0.71 per diluted share, which included a one–time gain related to the acquisition of certain assets of MDRNA's Hauppauge, NY facility. Adjusting for this item, earnings per diluted share were $0.65 for the three month period ended June 2009.

Today in Financial Reports...keeping you current

Receive free subspecialty "5-minute updates" via email

Pre-Budget Report response - GSK comments on patent box
GlaxoSmithKline, 12/11/09

Report: Acquisition Activity Down
HealthDataManagement, 12/08/09

Genzyme Provides Update on Cerezyme Supply and 2009 Financial Information
Genzyme, 12/07/09

 See all of Financial Reports